Breaking Stories

The Wall Street Journal: Eli Lilly COVID-19 antibody drug shipments paused over variant concerns


U.S. health officials have paused the distribution of two Eli Lilly & Co.

Covid-19 monoclonal antibody treatments because of data showing they aren’t effective against virus variants that are becoming increasingly common across the country.

The Department of Health and Human Services said Friday that it is immediately pausing all distribution of bamlanivimab and etesevimab together, as well as etesevimab alone to be paired with existing supplies of bamlanivimab, in the U.S. until further notice.

An expanded version of this article appears on

The Fed: Fed’s Rosengren says conditions may be in place for tapering bond purchases by year-end, with first interest rate hike by late 2022

Previous article

The Moneyist: Jamie Dimon insists his workers return to the office — here’s why that’s a bit rich

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *